Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational Phase II/III trial of VCN-01 in pediatric patients with advanced retinoblastoma

Next Previous
X
Search
Trial Profile

A registrational Phase II/III trial of VCN-01 in pediatric patients with advanced retinoblastoma

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 13 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VCN 01 (Primary)
  • Indications Retinoblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Theriva Biologics

    • Most Recent Events

    • 07 May 2024 According to a Theriva Biologics media release, results of phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma will help inform the planned Phase 2 trial design.
    • 30 Mar 2023 According to a Theriva Biologics media release, the company plans to hold a pre-IND meeting with the FDA (H2 2023) to discuss the clinical development and potential registration pathway for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma.
    • 11 Aug 2022 According to a Synthetic Biologics media release, the trial is expected to be initiated in the second half of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top